Goal Reached Thanks to every supporter — we hit 100%!

Goal: 1000 CNY · Raised: 1000 CNY

100.0%
Get alerts for future matching vulnerabilitiesLog in to subscribe
I. Basic Information for CVE-2023-30458
Vulnerability Information

Have questions about the vulnerability? See if Shenlong's analysis helps!
View Shenlong Deep Dive ↗

Although we use advanced large model technology, its output may still contain inaccurate or outdated information.Shenlong tries to ensure data accuracy, but please verify and judge based on the actual situation.

Vulnerability Title
N/A
Source: NVD (National Vulnerability Database)
Vulnerability Description
A username enumeration issue was discovered in Medicine Tracker System 1.0. The login functionality allows a malicious user to guess a valid username due to a different response time from invalid usernames. When one enters a valid username, the response time increases depending on the length of the supplied password.
Source: NVD (National Vulnerability Database)
CVSS Information
N/A
Source: NVD (National Vulnerability Database)
Vulnerability Type
N/A
Source: NVD (National Vulnerability Database)
Vulnerability Title
Medicine Tracker System 安全漏洞
Source: CNNVD (China National Vulnerability Database)
Vulnerability Description
Medicine Tracker System是Carlo Montero个人开发者的一个药物追踪系统。 Medicine Tracker System 1.0版本存在安全漏洞,该漏洞源于存在用户名枚举问题。攻击者可利用该漏洞通过判断响应时间猜测有效用户名
Source: CNNVD (China National Vulnerability Database)
CVSS Information
N/A
Source: CNNVD (China National Vulnerability Database)
Vulnerability Type
N/A
Source: CNNVD (China National Vulnerability Database)
Affected Products
VendorProductAffected VersionsCPESubscribe
-n/a n/a -
II. Public POCs for CVE-2023-30458
#POC DescriptionSource LinkShenlong Link
1Nonehttps://github.com/d34dun1c02n/CVE-2023-30458POC Details
AI-Generated POCPremium

No public POC found.

Login to generate AI POC
III. Intelligence Information for CVE-2023-30458
Please Login to view more intelligence information
IV. Related Vulnerabilities
V. Comments for CVE-2023-30458

No comments yet


Leave a comment